Chilmark Vice President Kenneth Kleinberg said that hospitals are deploying AI, image recognition, natural language processing, predictive analytics - and they’re doing so quickly.
A study using epilepsy patients undergoing surgery has given neuroscientists an opportunity to track in unprecedented detail the movement of a thought through the human brain, all the way from inspiration to response.
Remote patient monitoring company LindaCare announced on Friday that they landed $8.6 million (€7 million) in Series B funding with participation by Philips, PMV, Capricorn ICT Arkiv, and Connecticut Innovations.
A team of South Korean researchers is the latest to tout a smart, glucose-sensing contact lens. In a research article published today in Science Advances, the team described soft lenses carrying a tiny LED light that automatically turns off in the event of high glucose levels, as well as their efforts to test the lens in vivo.
Scientists from the University of Alberta have unveiled ProjectDR, technology that uses augmented reality (AR) to display medical images such as CT and MRI scans directly onto a patient’s body.
Tmunity Therapeutics is looking to bring better and safer T-cell therapies for both solid tumors and blood cancers and has scored a $100 million series A to propel it on its journey
Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the U.S.
The commercial life for Novartis’ Arzerra outside the U.S. is coming to an end.
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods. Immunotherapies are breakthrough treatments that stimulate the patient’s immune cells to attack the tumor through the recognition of aberrant molecules called tumor antigens. They can be very effective, but currently can only cure a minority of patients with solid tumors. Researchers and physicians are now looking into ways of increasing the precision and strength of the immune attack on the tumor. Dendritic cell vaccines One approach is the “dendritic cell vaccine”. Dendritic cells are specialized immune cells whose role is to capture antigens from foreign bodies and present them to the immune system’s killer T cells, which will then attack and destroy the invaders. For the vaccine, dendritic cells are taken out of the patient, “force-fed” with tumor antigens, and finally re-injected back into ...
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. On Monday, the company revealed Phase IIIb data that demonstrated the drug is also effective in reducing the number of episodic headaches in patients who have not responded to previous treatments.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.